Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
 as Schedule II Drug - EconoTimes)
PHOENIX, March 23, 2017 -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or the “Company") today announced that the Drug Enforcement Agency (“DEA”) has issued an interim final rule that would result in Syndros™ (dronabinol oral solution) being placed in Schedule II of the Controlled Substances Act.
On July 1, 2016, the Food and Drug Administration (“FDA”) approved the New Drug Application for Syndros.
Dr. Santosh Vetticaden, Ph.D., M.D., Interim CEO, and Chief Medical Officer, stated, “Insys is looking forward to bringing this new drug product to chemotherapy patients to help alleviate their nausea and vomiting and AIDS patients with anorexia associated weight loss, respectively.”
“We look forward to interacting with the FDA to finalize the labeling and subsequent launch of Syndros in the second half of 2017,” concluded Vetticaden.
Important Safety Information
Syndros is a cannabinoid indicated in adults for the treatment of:
- Anorexia associated with weight loss in patients with AIDS, and
- Nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments
The use of dronabinol may cause psychiatric and cognitive effects and impair mental and/or physical abilities.
Patients with cardiac disorders may experience hypotension, hypertension, syncope or tachycardia.
May cause disulfiram-like reaction.
Weigh the potential risk versus benefits before prescribing Syndros to patients with a history of seizures, including those requiring anti-epileptic medication or other factors that lower the seizure threshold.
Assess risk for abuse or misuse in patients with a history of substance abuse or dependence, prior to prescribing Syndros and monitor for the development of associated behaviors or conditions.
Consider dose reduction or discontinuation, if worsening of symptoms while on treatment.
The safety and effectiveness of Syndros have not been established in pediatric patients.
About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. Insys currently markets one product, SUBSYS® (fentanyl sublingual spray) but has received approval for the marketing of SYNDROS™ (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with high unmet need.
SUBSYS® and SYNDROS™ are trademarks of Insys Development Company, Inc., a subsidiary of Insys Therapeutics, Inc.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding (i) the anticipated scheduling and launch of SYNDROS™, (ii) the belief that the Company has the potential to benefit patients in areas of unmet medical needs and (iii) the belief that SYNDROS has distinct advantages over the current formulation of dronabinol in soft gel capsule. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. For a description of these risks facing the company, please see the risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2015 and any subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise these statements, except as may be required by law.
Contact: Lisa M. Wilson 212-452-2793 E: [email protected]
